{
    "nct_id": "NCT03248882",
    "official_title": "A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, PARALLEL GROUP STUDY TO EVALUATE SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-05221304 ADMINISTERED DAILY FOR 16-WEEKS TO ADULT SUBJECTS WITH NONALCOHOLIC FATTY LIVER DISEASE",
    "inclusion_criteria": "* Body Mass Index >= 25 kg/m2\n* Body Weight > 50 kg\n* Liver fat (assessed via MRI-PDFF) >= 8%\n* Biopsy-proven NASH - diagnosed in previous 24-months\n* Presumed NASH - per Sponsor's definition\n* NAFLD with minimal inflammation/fibrosis\n* Features of Metabolic Syndrome\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 70 Years",
    "exclusion_criteria": "* Alcohol-induced steatohepatitis or other forms of chronic liver disease\n* Positive for Hepatitis B, Hepatitis C, or Human Deficiency Virus\n* Severe Renal Impairment\n* Contraindications for MRI",
    "miscellaneous_criteria": ""
}